Investigational Drug Information for ONC201
✉ Email this page to a colleague
What is the drug development status for ONC201?
ONC201 is an investigational drug.
There have been 28 clinical trials for ONC201.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2022.
The most common disease conditions in clinical trials are Glioma, Glioblastoma, and Endometrial Neoplasms. The leading clinical trial sponsors are Oncoceutics, Inc., Chimerix, and National Cancer Institute (NCI).
There are fourteen US patents protecting this investigational drug and one hundred and eighty-one international patents.
Summary for ONC201
| US Patents | 14 |
| International Patents | 181 |
| US Patent Applications | 56 |
| WIPO Patent Applications | 11 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 2 (2022-09-01) |
| Vendors | 55 |
Recent Clinical Trials for ONC201
| Title | Sponsor | Phase |
|---|---|---|
| A Study of ONC201 for Refractory Meningioma | Chimerix | Phase 1 |
| A Study of ONC201 for Refractory Meningioma | University of Nebraska | Phase 1 |
| Testing ONC201 to Prevent Colorectal Cancer | National Cancer Institute (NCI) | Phase 1 |
Clinical Trial Summary for ONC201
Top disease conditions for ONC201
Top clinical trial sponsors for ONC201
US Patents for ONC201
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ONC201 | ⤷ Sign Up | 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]- pyrimidin-5 (1h)-one, salts thereof and methods of using the same in combination therapy | Oncoceutics, Inc. (Philadelphia, PA) | ⤷ Sign Up |
| ONC201 | ⤷ Sign Up | Imipridones for gliomas | Oncoceutics, Inc. (Philadelphia, PA) | ⤷ Sign Up |
| ONC201 | ⤷ Sign Up | 7-Benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-A]pyrido[3,4-E]pyrimidin-5(1H)-one, analogs thereof, and salts thereof and methods for their use in therapy | Oncoceutics, Inc. (Philadelphia, PA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ONC201
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ONC201 | Australia | AU2014244117 | 2033-03-13 | ⤷ Sign Up |
| ONC201 | Australia | AU2014349150 | 2033-03-13 | ⤷ Sign Up |
| ONC201 | Australia | AU2019201896 | 2033-03-13 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
